GlassScriptPhysician profile
James B Gardner
NPI 1487824637
$1,531.58
in general payments reported to CMS, 2019-2025
21 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $389 · 2022: $109 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $307.19 | 2019-2020 | |
| Medtronic Minimed, INC. | $214.33 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $125.28 | 2025 | Triptodur |
| Ultragenyx Pharmaceutical INC. | $120.64 | 2019-2020 | |
| Csl Behring | $105.21 | 2019 | |
| Insulet Corporation | $103.81 | 2019-2022 | |
| Abbvie INC. | $87.49 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $87.40 | 2019 | |
| Endo Pharmaceuticals INC. | $48.90 | 2019-2020 | |
| Grifols USA, LLC | $46.29 | 2019 | |
| Arbor Pharmaceuticals, INC. | $42.27 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $39.58 | 2020-2022 | |
| Becton, Dickinson and Company | $31.44 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $28.22 | 2019 | |
| Lilly USA, LLC | $25.31 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.61 | 2019 | |
| Companion Medical, INC. | $21.83 | 2020 | |
| Abbott Laboratories | $19.80 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.35 | 2020 | |
| Tandem Diabetes Care, INC. | $17.06 | 2020 | |
| Shire North American Group INC | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.